When the κ-subtype of opioid receptor was first distinguished, there was tremendous interest in developing analgesics that would provide pain-relief without activating the reward pathways stimulated by morphine-like μ-opioids. A nonaddictive opioid has been a holy grail of medicinal chemistry ever since Friedrich Serturner isolated morphine from opium in 1804. Selective κ-agonists were developed, but quickly found to produce different problems including dysphoria, diuresis, and constipation. In addition, their maximal analgesic effects were weaker than μ-opioids in rodents. But interest in κ-opioids as therapeutic tools did not completely die; Shippenberg and colleagues found that κ-agonists reduced the rewarding effects of co-administered addictive drugs; κ-opioid analgesia using pentazocine was seen as an alternative for pain control in people with a risk of drug abuse; and κ-agonists entered clinical trials for the treatment of pain and itch (see Millan, 1990).
Although enthusiasm for agonists waned, interest in κ-antagonists as therapeutic tools got a boost when Carlezon and colleagues showed their activity in the forced swim assay, predictive of antidepressant activity (Mague et al, 2003). Following on that study, we reported that κ-antagonism blocked stress-induced potentiation of cocaine reinforcement (McLaughlin et al, 2003). Numerous studies have replicated and extended those findings showing the utility of κ-antagonists to block stress-induced reinstatement of extinguished cocaine- and ethanol-seeking, block μ-opioid and cannabinoid withdrawal signs, and block the aversive effects of nicotine. All these effects of κ-antagonists can be attributed to block of the actions of endogenous dynorphins, which are κ-selective opioid peptides released during the stress response (Land et al, 2008). Consistent with the dysphoric effects of κ-agonist drugs and natural κ-opioids isolated from the plant Salvia divinorum, endogenous dynorphins encode a component of the anxiogenic and dysphoric responses to stressful experience.
Thus, κ-opioid antagonists show promise as therapeutic tools to promote stress resilience that may be effective in treating certain forms of anxiety, depression, and addiction disorders, as stress-hypersensitivity exacerbates each of these syndromes. However, selective κ-opioid antagonists have been known since their initial development by Portoghese and Takemori more than 20 years ago to have remarkably long durations of action. Although this property might be considered a therapeutic advantage (as infrequent dosing may be sufficient and missed doses would be less concerning), the lack of understanding of its basis has slowed drug development. We recently reported (Bruchas et al, 2007; Melief et al, 2010) that the long action was not a result of κ-receptor downregulation or drug persistence, but rather that these ligands were not truly competitive antagonists; instead their effects were caused by the activation of c-Jun N-terminal kinase (JNK) following κ-receptor binding (Figure 1). We think that JNK activation phosphorylates a component of the κ-receptor signaling complex, thus preventing G-protein activation and causing long-lasting receptor inactivation. This mechanism predicts that low-efficacy ligands that bind to κ-receptors without activating JNK may be short-acting antagonists. Conventional, competitive κ-antagonists may more easily gain approval.
The therapeutic promise of κ-agonists has also been recently revived by studies showing that their dysphoric effects require activation of G-protein receptor kinase, arrestin recruitment and subsequent p38 MAPK activation, whereas their analgesic effects do not (Bruchas and Chavkin, 2010). As evident from ligands initiating μ-opioid signaling, some analgesic opioids including fentanyl effectively recruit arrestin, whereas morphine is an excellent analgesic, but does not recruit arrestin. The realization that different agonists binding to the same receptor can produce different actions has been variously called ‘biased agonism’, ‘functional selectivity’, and ‘ligand directed signaling’ (see Melief et al, 2010). On the basis of this concept, an analgesic κ-opioid that did not recruit arrestin might not produce dysphoria (Figure 1). A formulation of such a ligand, combined with a peripherally restricted κ-antagonist to block the constipating and diuretic effects, might result in the long-sought nonaddictive opioid analgesic. These are exciting times in the κ-world.
References
Bruchas MR, Chavkin C (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) 210: 137–147.
Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S et al (2007). Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282: 29803–29811.
Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28: 407–414.
Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens Jr WC et al (2003). Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323–330.
McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674–5683.
Melief EJ, Miyatake M, Bruchas MR, Chavkin C (2010). Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci USA 107: 11608–11613.
Millan MJ (1990). Kappa-opioid receptors and analgesia. Trends Pharmacol Sci 11: 70–76.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C Chavkin has no conflicts of interest or consulting relationships to disclose, but has received outside compensation for seminars on his NIH-funded research during the past 3 years at: AstraZeneca, NIDA, UC Irvine, Uniformed Services University, University of Minnesota, Sepracor, Eli Lilly, Adolor, and Vanderbilt. In addition, he has received outside compensation for reviewing grants for CSR-NIH and NIDA.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chavkin, C. The Therapeutic Potential of κ-Opioids for Treatment of Pain and Addiction. Neuropsychopharmacol 36, 369–370 (2011). https://doi.org/10.1038/npp.2010.137
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2010.137
This article is cited by
-
Effects of the novel selective κ-opioid receptor agonist NP-5497-KA on morphine-induced reward-related behaviors
Scientific Reports (2023)
-
Social approach and social vigilance are differentially regulated by oxytocin receptors in the nucleus accumbens
Neuropsychopharmacology (2020)
-
Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies
Scientific Reports (2020)
-
Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys
Psychopharmacology (2020)
-
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
European Journal of Nuclear Medicine and Molecular Imaging (2020)